BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 8
• 9
• 10
• 11
• 12
• 13
• 15
• 16
• 17
• 18
• 19
• 22
• 23
• 24
• 25
• 26
• 29
• 30
• 31

• AAOS Updates Clinical Practice Guideline for Management of Acute Isolated Meniscal Pathology

  The American Academy of Orthopaedic Surgeons (AAOS) issued a new Clinical Practice Guideline (CPG) for the Management of Acute Isolated Meniscal Pathology, which was created to help the orthopaedic community treat patients suspected of or diagnosed with an acute isolated meniscal tear.

  July 1, 2024

   · 

  6 min read
• Company Reports Inducement Grants to Non-Executive New Employee Under Nasdaq Listing Rule 5635(C)(4) - July 01, 2024

  Axogen, Inc. announced making an inducement grant on July 1, 2024, under NASDAQ listing rule 5635 in connection with the hire of a new non-executive employee.

  July 1, 2024

   · 

  3 min read
• Korro Joins the Russell 2000®, Russell 3000®, and Russell Microcap® Indexes

  Korro Bio, Inc. announced that it has been added to the Russell 2000®, Russell 3000®, and the Russell Microcap® Indexes as part of the annual reconstitution, effective at the open of US equity markets today, Monday, July 1.

  July 1, 2024

   · 

  6 min read
• Solid Biosciences Joins the Russell 3000® Index

  Solid Biosciences Inc. announced that the Company has been added to the broad-market Russell 3000® Index as part of the annual reconstitution, effective at the open of US equity markets, Monday, July 1st 2024.

  July 1, 2024

   · 

  5 min read
• Aileron Therapeutics to be Included in the Russell Microcap® Index

  Aileron Therapeutics, Inc. announced that the Company is set to join the Russell Microcap® Index at the conclusion of the 2024 Russell U.S. Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024.

  July 1, 2024

   · 

  3 min read
• NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC’s Potential as a Disease Modifying Drug

  NeuroSense Therapeutics Ltd. reported statistically significant results from the 12-month data analysis of the PARADIGM Phase 2b study evaluating PrimeC in people living with Amyotrophic Lateral Sclerosis.

  July 1, 2024

   · 

  8 min read
• INOVIO Added to Russell 2000® Index Effective July 1, 2024

  INOVIO announced its inclusion in the Russell 2000® Index as part of the annual reconstitution of the Russell stock indexes.

  July 1, 2024

   · 

  3 min read
• N-Power Medicine Emerges with Series B Funding to Bolster Access to Innovative Oncology Clinical Trials

  N-Power Medicine, a company reinventing the clinical trial process, announced the initial close of a Series B funding round, raising its total funding to date to $72 Million.

  July 1, 2024

   · 

  4 min read
• Sera Prognostics Added to Russell 2000 and 3000 Indexes Following Conclusion of 2024 Indexes Annual Reconstitution

  Sera Prognostics Inc. announced that as a result of the annual Russell Reconstitution being finalized on June 28, 2024, the Company has been added to the Russell Small-Cap 2000 and Russell 3000 indexes effective with the opening of equity markets today.

  July 1, 2024

   · 

  5 min read
• Capricor Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes

  Capricor Therapeutics announced that the Company is set to join the Russell 2000® Index and the broad-market Russell 3000® Index, effective at the open of U.S. equity markets, July 1, 2024.

  July 1, 2024

   · 

  5 min read